Novartis Ag (NVS) Common Equity (2009 - 2026)

Novartis Ag has disclosed Common Equity across 18 years of filings, most recently posting $41.9 billion for Q2 2026.

• In Q2 2026, Common Equity changed 0.26% year-over-year to $41.9 billion; the TTM figure through Jun 2026 stood at $41.9 billion (changed 0.26% YoY), while the FY2025 annual figure was $46.5 billion, up 5.49% from the prior year.
• Common Equity came in at $41.9 billion for Q2 2026 at Novartis Ag, up from $38.9 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $63.0 billion in Q2 2022 to a low of $38.2 billion in Q3 2023.
• Average Common Equity over 5 years is $47.6 billion, with a median of $44.4 billion recorded in 2024.
• Year-over-year, Common Equity rose 21.97% in 2022 and slumped 37.2% in 2023.
• Over 5 years, Common Equity stood at $59.4 billion in 2022, then declined by 21.33% to $46.8 billion in 2023, then retreated by 5.61% to $44.1 billion in 2024, then increased by 5.49% to $46.5 billion in 2025, then decreased by 9.89% to $41.9 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $41.9 billion in Q2 2026, $38.9 billion in Q1 2026, and $46.5 billion in Q4 2025.